Peptides DB
Research-centric peptide and protocol reference hub
Study 43 of 46Orforglipron (LY-3502970) literatureObesity pillars · RCTHigh-impact journal2026

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.

Orforglipron 17.2 mg resulted in a significant mean body weight reduction of -13.5% at 72 weeks compared to placebo, but the clinical relevance may vary by sex.

Read at Obesity pillarsAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
14
Preclinical
9
Observational
1
Open-label
14
Randomised · this one
8
Reviews

Summary and findings

This post hoc analysis evaluated the efficacy and safety of orforglipron in adults with a BMI of 27 to less than 30 kg/m² and adiposity-related complications. Participants received either orforglipron at doses of 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks. The study reported a significant reduction in body weight for the highest dose compared to placebo.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.2026

Abstract

The authors’ words, as Obesity pillars supplied them

<h4>Background</h4>Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to <30 kg/m<sup>2</sup> and adiposity-related complications have not been characterized. Adults with overweight and an adiposity-related complication are at substantial cardiometabolic risk, and obesity medications are recommended for this group.<h4>Methods</h4>This was a post-hoc analysis of the ATTAIN-1 trial (NCT05869903), a phase 3, randomized, double-blind, placebo-controlled trial in which adults without diabetes and with obesity or overweight were randomized 3:3:3:4 to once-daily oral orforglipron 5.5, 9, or 17.2 mg or placebo for 72 weeks. The present analysis included the subset of randomized participants with BMI ≥27 to <30 kg/m<sup>2</sup> and ≥1 adiposity-related complication. Endpoints included change from baseline to Week 72 the percent change in body weight, BMI, categorical weight-loss, waist circumference, lipids, patient-reported outcomes, and safety. Effect estimates are reported using efficacy and treatment-regimen estimands. Efficacy endpoints were also reported per sex subgroup.<h4>Results</h4>This analysis included 260 participants (orforglipron 5.5 mg: 56; 9 mg: 64; 17.2 mg: 62; placebo: 78). At Week 72, orforglipron was associated with greater mean percent body weight reduction (17.2 mg: -13.5%) versus placebo (-0.3%) (nominal p < 0.001). Females experienced up to -18.8% mean body weight reduction and males up to -10.0%. Orforglipron was associated with improvements in waist circumference, triglycerides, and low-density lipoprotein cholesterol, as well as improvements in patient-reported outcomes. Safety profile was consistent with previous trials with predominantly mild-to-moderate gastrointestinal events.<h4>Conclusion</h4>In this post hoc analysis of ATTAIN-1, participants with BMI ≥27 to <30 kg/m<sup>2</sup> and ≥1 adiposity-related complication, orforglipron was associated with improvements in anthropometric and cardiometabolic parameters, with a safety profile broadly consistent with the overall ATTAIN-1 trial (ClinicalTrials.gov identifier: NCT05869903).

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Orforglipron (LY-3502970) corpus

ASafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%reviewAOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanDOrforglipron for Obstructive Sleep Apnea: Research Summary.JAMA · 2026reviewAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.HumanBPreferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes, obesity & metabolism · 2025 · n=800 · 84.2% preferred Treatment A vs 15.8% for Treatment B.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.Human